SkinHealth Systems (SKIN) Cash & Equivalents (2020 - 2026)

SkinHealth Systems (SKIN) has reported Cash & Equivalents for 7 consecutive years, with $206.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 2.8% year-over-year to $206.1 million in Q2 2026; TTM through Jun 2026 was $206.1 million, a 2.8% decrease from a year earlier, with the FY2025 full-year figure at $232.7 million, down 37.13% from the prior year.
• Cash & Equivalents was $206.1 million for Q2 2026 at SkinHealth Systems, up from $204.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $859.2 million in Q1 2022 and troughed at $204.4 million in Q1 2026.
• A 5-year average of $448.2 million and a median of $408.8 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 31109.19% in 2022 and sank 45.22% in 2026, its largest moves.
• Over 5 years, Cash & Equivalents stood at $568.2 million in 2022, then declined by 7.95% to $523.0 million in 2023, then decreased by 29.25% to $370.1 million in 2024, then tumbled by 37.13% to $232.7 million in 2025, then dropped by 11.43% to $206.1 million in 2026.
• The last three Cash & Equivalents figures came in at $206.1 million (Q2 2026), $204.4 million (Q1 2026), and $232.7 million (Q4 2025), per Business Quant data.